Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bioheart, a biotechnology company, and Monebo have signed a licensing agreement that provides Bioheart the right to distribute Monebo's heart monitoring, arrhythmia and A-Fib analysis technologies.
Subscribe to our email newsletter
The license agreement also includes Monebo’s call center management software. Bioheart plans to immediately begin selling the CardioBelt system worldwide, including the US market, as a complementary technology to the Bioheart 3370 at-home heart failure monitor.
The Bioheart-Monebo system allows heart patients to be monitored from the comfort of their own home. The system consists of the easy-to-use CardioBelt ECG acquisition device and ECGAnalyzer monitoring software. It is designed for patient ease of use, and to allow health care professionals to quickly obtain accurate information on their patient’s electrocardiogram (ECG).
The ECGAnalyzer decision support system is designed to aid health care professionals to interpret ECG data and risk-stratify their patients. It can be used in a real-time application or for post-processing and will run in any PC or server-based environment, the company said.
According to the company, ECGAnalyzer displays the ECG waveform, makes the critical measurements, and performs rhythm interpretation on up to 16 different rhythms. ECGAnalyzer can also be used in conjunction with the CardioBelt ECG acquisition device, or as a stand-alone device to interpret up to 16 leads of ECG data.